USE OF ANTICOAGULANTS IN COVID-19 PATIENTS AS A PREVENTIVE EFFORT FOR HEART FAILURE MORTALITY

Abstract

Background: Thrombosis and hypercoagulable states are complications that can arise in COVID-19 and heart failure patients. This occurs due to a cytokine reaction, leading to the activation and increase of coagulation factors. This condition can lead to complications such as DVT, VTE, and PE, which will increase the severity and mortality of the patient's disease. Anticoagulants are one of the effective therapies to prevent and treat various types of thromboembolic diseases. Heparin and enoxaparin are commonly used anticoagulants in hospitals.

Objective: This study aimed to determine whether the use of anticoagulants was associated with the mortality rate in COVID-19 patients diagnosed with heart failure.

Methods: This study was conducted using a cross-sectional analytic design. The  sample consisted of 71 patients, including 51 who used enoxaparin, 15 who used heparin, and 5 who used a combination of both. After the data was obtained, it was then processed and presented in tabular form.

Results: While initial findings suggested that enoxaparin use was associated with lower mortality rates compared to heparin or a combination of both, subsequent analysis revealed no statistically significant difference in mortality rates among patients receiving enoxaparin, heparin, or a combination (p-value = 0,191).

Conclusion: There was no significant difference in mortality rates between patients given enoxaparin, heparin, or a combination.